SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: I. Luttichuys who wrote (123)11/21/1996 3:27:00 AM
From: F.S. Wang   of 1762
 
Hi,

I heard the ASH abstract about IDEC-C2B8/CHOP chemoimmunotherapy. It showed overall response rate for patients who completed treatment was 100% (60% CR and 40% PR). and most bcl-2(PCR)positive patient have converted to PCR negative in blood and/or bone marrow; this has not been seen with standard dose CHOP alone. They believed the data suggested that the combination of IDEC-C2B8 and CHOP chemoimmunotherapy is more efficacious than CHOP alone with minimal (and non-overlapping)additional toxicity. Anybody knows FDA action at this time, thank you,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News